| Date | Form | Description | Docs | XBRL | Pages |
| 02/12/18 | DEF 14A | Definitive proxy statements |
|
36 | |
| 01/30/18 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
14 | |
| 01/30/18 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
14 | |
| 01/26/18 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
36 | |
| 01/23/18 | 8-K | Current report filing |
|
3 | |
| 01/09/18 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
148 |
| 12/12/17 | 8-K | Current report filing |
|
3 | |
| 11/22/17 | 8-K | Current report filing |
|
3 | |
| 11/17/17 | 8-K | Current report filing |
|
3 | |
| 11/17/17 | 8-K | Current report filing |
|
48 |
Latest News & Events
Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
Read More...Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Read More...Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology
Read More...